It was announced by International Stem Cell Corp. sometime last week that human parthenogenetic stem cell lines (“hpSC”), created by scientists from its Research and Therapeutic Development Group, have sustained the ability to conserve the vital properties of immortal stem cells throughout extended laboratory cultivation.
Dr. Andrey Semechkin, ISCO’s СЕО, says: “The ability of a stem cell line to maintain stable properties during long-term cultivation is one of the necessary properties that stem cells must have in order to be used in cell-based therapies. This property allows an almost unlimited increase in the amount of cells available for production of therapeutic derivatives.”
Best Damn Penny Stocks, a leading financial publication, is pleased to alert investors of stocks on the move.
Sign Up for our Free Stock Newsletter
ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB):
International Stem Cell Corporation is a California-based biotechnology company focused on therapeutic and research products. ISCO's core technology, parthenogenesis, results in creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing sexes, ages and racial groups. This offers the potential to create the first true stem cell bank, UniStemCell™, while avoiding the ethical issue of using fertilized eggs. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology
Sign up for the free Best Damn Penny Stocks newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website
Please click here to read the full
disclaimer